Angiodynamics

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Angiodynamics sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials 2 currently recruiting 6 completed later-stage tilt top decile by trial count

Angiodynamics: 12 sponsored US clinical trials, 2 recruiting.

Angiodynamics sponsors 12 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 6 completed. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Stage III Pancreatic Cancer, with 2 trials.

Top-decile sponsor footprint

Angiodynamics ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 1
Phase 4 1

Where Angiodynamics enrollment is open (later-stage tilt)

2 recruiting of 12 indexed (17% open); 6 completed (50%).

Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Stage III Pancreatic Cancer (2 trials), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Angiodynamics: open-pipeline peers nationwide

Peers matched on 12 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Angiodynamics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 468101214 0%5%10%15%20% Total trials Recruiting share AngiodynamicsAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.ApnimedAdageneAgendiaAkamis BioAnthos Therapeutics
Angiodynamics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Angiodynamics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this Angiodynamics page

12 registered trials is a research-attention snapshot, not an endorsement of Angiodynamics or any single study.

  • 2 of Angiodynamics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Stage III Pancreatic Cancer is the condition Angiodynamics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Stage III Pancreatic Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Angiodynamics pipeline card: 12 registered trials from official public datasets.Report a data error.